Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRAS^G12D mutated pancreatic cancer in vivo model.

ABSTRACT: Pancreatic cancer (PC) has a very low survival rate mainly due to late diagnosis and refractoriness to therapies. The latter also cause adverse effects negatively affecting the patients' quality of life, often requiring dose reduction or discontinuation of scheduled treatments, compromising the chances of cure. We explored the effects of a specific probiotic blend on PC mice xenografted with KRAS wild-type or KRASG12D mutated cell lines alone or together with gemcitabine+nab-paclitaxel treatment to then assess tumor volume and clinical pathological variables. Beside a semi-quantitative histopathological evaluation of murine tumor and large intestine samples, histochemical and immunohistochemical analyses were carried out to evaluate collagen deposition, proliferation index Ki67, immunologi

SUBMITTER: Panebianco C 

PROVIDER: S-EPMC10076501 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature